Skip to content
Attgeno

Attgeno

Menu

  • Supernitro
  • About us
    • Management Team
    • Board of Directors
  • News
  • Contact & Info

    2020, Feb

    Clinical phase 1 FIH study approved by Swedish MPA

    2020, Feb
    attgenoadmin February, 2020March, 2021 R&D2
    • ← New NO-donating substances
    • Second financial round oversubscribed rights issue →
    Attgeno

    Home of Supernitro

    Contact us

    Attgeno AB
    Fogdevreten 2A
    171 65 Solna

    SWEDEN

    Phone +46 70 645 78 27

    E-mail info@attgeno.com

    Attgeno

    • Supernitro
    • About us
      • Board of Directors
      • Management Team
    • Contact & Info
    Copyright © 2023 Attgeno.    
    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok